Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy

Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy

Chimeric antigen receptor (CAR) T-cell therapies have shown impressive results in patients with hematological malignancies; however, little success has been achieved in the treatment of solid tumors. Recently, macrophages (MΦs) were identified as an additional candidate for the CAR approach, and ini...

Full description

Bibliographic Details
Main Authors: Abken, H. (Author), Buchegger, T. (Author), Falk, C.S (Author), Holzinger, A. (Author), Kloos, D. (Author), Kloth, C. (Author), Kuehle, J. (Author), Lachmann, N. (Author), Lenz, D. (Author), Meyer, J. (Author), Morgan, M. (Author), Moritz, T. (Author), Paasch, D. (Author), Schambach, A. (Author), Stamopoulou, A. (Author), von Kaisenberg, C.S (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
Cancer
Cancer immunotherapy
Chimeric antigen receptors
Hematopoietic stem cells
Macrophages
Phagocytosis
Solid tumors
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items